One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer.
Spriggs, David R. MD 1,2,; Fleming, Gini F. MD 3,4,,
doi : 10.1200/JCO.23.00102
Volume 41(25) pgs. 4063-4187 September 1, 2023
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis.
Bristow, Robert E.; Tomacruz, Rafael S.; Armstrong, Deborah K.; Trimble, Edward L.; Montz, F. J.
doi : 10.1200/JCO.22.02765
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
Ozols, Robert F.; Bundy, Brian N.; Greer, Benjamin E.; Fowler, Jeffrey M.; Clarke-Pearson, Daniel; Burger, Robert A.; Mannel, Robert S.; DeGeest, Koen; Hartenbach, Ellen M.; Baergen, Rebecca
doi : 10.1200/JCO.22.02766
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
Siefker-Radtke, Arlene O. MD 1,,; Cauley, Diana PharmD 2; Alhalabi, Omar MD 1,
doi : 10.1200/JCO.23.00987
Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL.
Maese, Luke D. DO 1,; Pulsipher, Michael A. MD 1,,
doi : 10.1200/JCO.23.00594
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.
Bestvina, Christine M. MD 1,; Garassino, Marina C. MD 1; Neal, Joel W. MD, PhD 2,; Wakelee, Heather A. MD 2,; Diehn, Maximilian MD, PhD 3,; Vokes, Everett E. MD 1,
doi : 10.1200/JCO.23.00258
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.
Bekaii-Saab, Tanios S. MD 1,,; Yaeger, Rona MD 2,; Spira, Alexander I. MD 3,4,5,; Pelster, Meredith S. MD 6,; Sabari, Joshua K. MD 7,; Hafez, Navid MD 8,; Barve, Minal MD 9,; Velastegui, Karen BSc 10,; Yan, Xiaohong PhD 10,; Shetty, Aditya MD 10,; Der-Torossian, Hirak MD 10,; Pant, Shubham MBBS 11,
doi : 10.1200/JCO.23.00434
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
O'Donnell, Peter H. MD 1,; Milowsky, Matthew I. MD 2,; Petrylak, Daniel P. MD 3,; Hoimes, Christopher J. DO 4,; Flaig, Thomas W. MD 5,; Mar, Nataliya MD 6,; Moon, Helen H. MD 7,; Friedlander, Terence W. MD 8,; McKay, Rana R. MD 9,; Bilen, Mehmet A. MD 10,; Srinivas, Sandy MD 11,; Burgess, Earle F. MD 12,; Ramamurthy, Chethan MD 13,; George, Saby MD 14,; Geynisman, Daniel M. MD 15,; Bracarda, Sergio MD 16,; Borchiellini, Delphine MD 17,; Geoffrois, Lionnel MD 18,; Maroto Rey, Jose Pablo MD 19,; Ferrario, Christiano MD 20,; Carret, Anne-Sophie MD 21,; Yu, Yao PhD 21,; Guseva, Maria MD, PharmD 22,; Homet Moreno, Blanca MD, PhD 23,; Rosenberg, Jonathan E. MD 24,,
doi : 10.1200/JCO.22.02887
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.
Hogan, Laura E. MD 1,; Brown, Patrick A. MD 2,; Ji, Lingyun PhD 3,; Xu, Xinxin MS 4; Devidas, Meenakshi PhD 5,; Bhatla, Teena MD 6; Borowitz, Michael J. MD, PhD 7,; Raetz, Elizabeth A. MD 8,; Carroll, Andrew PhD 9; Heerema, Nyla A. PhD 10; Zugmaier, Gerhard MD 11,; Sharon, Elad MD, MPH 12; Bernhardt, Melanie B. PharmD 13,; Terezakis, Stephanie A. MD 14; Gore, Lia MD 15,; Whitlock, James A. MD 16,; Hunger, Stephen P. MD 17,; Loh, Mignon L. MD 18,19
doi : 10.1200/JCO.22.02200
Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.
Pieters, Rob MD, MSc, PhD 1,2,,; de Groot-Kruseman, Hester PhD 1,2; Fiocco, Marta PhD 1,2,3,4; Verwer, Femke MSc 1,2; Van Overveld, Merian MSc 1; Sonneveld, Edwin PhD 1,2; van der Velden, Vincent PhD 5,; Beverloo, H. Berna PhD 6; Bierings, Marc MD, PhD 1,2,; Dors, Natasja MD 1; de Haas, Valerie MD, PhD 1,2; Hoogerbrugge, Peter MD, PhD 1; Van der Sluis, Inge MD, PhD 1,; Tissing, Wim MD, PhD 1; Veening, Margreet MD, PhD 1; Boer, Judith PhD 1; Den Boer, Monique PhD 1
doi : 10.1200/JCO.22.02705
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
Stintzing, Sebastian MD 1,2,; Heinrich, Kathrin MD 3,; Tougeron, David MD, PhD 4,; Modest, Dominik Paul MD 1,; Schwaner, Ingo MD 5,; Eucker, Jan MD 6; Pihusch, Rudolf MD 7; Stauch, Martina MD 8; Kaiser, Florian MD 9,; Kahl, Christoph MD 10,11,; Karthaus, Meinolf MD 12,; Muller, Christian MD 13,; Burkart, Christof MD 14,; Reinacher-Schick, Anke MD 15,; Kasper-Virchow, Stefan MD 16,; Fischer von Weikersthal, Ludwig MD 17,; Krammer-Steiner, Beate MD 18; Prager, Gerald Wolfgang MD 19,; Taieb, Julien MD 4,20,; Heinemann, Volker MD 3,21,,
doi : 10.1200/JCO.22.01420
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Ingham, Matthew MD 1,,; Allred, Jacob B. MS 2; Chen, Li PhD 3,; Das, Biswasjit PhD 3; Kochupurakkal, Bose PhD 4,; Gano, Katherine BS 2; George, Suzanne MD 5,; Attia, Steven MD 6,; Burgess, Melissa A. MD 7,; Seetharam, Mahesh MD 8,; Boikos, Sosipatros A. MD 9,; Bui, Nam MD 10,; Chen, James L. MD 11,; Close, Julia L. MD 12; Cote, Gregory M. MD, PhD 13,; Thaker, Premal H. MD 14,; Ivy, S. Percy MD 15; Bose, Sminu MD 1; D'Andrea, Alan MD 4,5,; Marino-Enriquez, Adrian MD 16; Shapiro, Geoffrey I. MD, PhD 4,5,; Schwartz, Gary K. MD 1,
doi : 10.1200/JCO.23.00402
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
Hilton, Laura K. PhD 1,2; Ngu, Henry S. MBChB 1,; Collinge, Brett BSc (Hons) 1,3; Dreval, Kostiantyn PhD 2,4; Ben-Neriah, Susana MSc 1; Rushton, Christopher K. PhD 2,; Wong, Jasper C.H. MSc 1; Cruz, Manuela BSc 2; Roth, Andrew PhD 5; Boyle, Merrill BSc 1; Meissner, Barbara PhD 1; Slack, Graham W. MD 1,3,; Farinha, Pedro PhD 1,3; Craig, Jeffrey W. PhD 1,3,; Gerrie, Alina S. MD 1,6,; Freeman, Ciara L. PhD 7,; Villa, Diego MD 1,6,; Rodrigo, Judith A. MD 8,9; Song, Kevin MD 8,9,; Crump, Michael MD 10,; Shepherd, Lois MDCM 11,12; Hay, Annette E. MBChB 11,12,; Kuruvilla, John MD 10,; Savage, Kerry J. MD 1,6,; Kridel, Robert PhD 10,; Karsan, Aly PhD 4,; Marra, Marco A. PhD 1,4,13; Sehn, Laurie H. MD 1,6,; Steidl, Christian MD 1,3,; Morin, Ryan D. PhD 1,2,4,; Scott, David W. PhD 1,6,,
doi : 10.1200/JCO.23.00570
Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.
Roeland, Eric J. MD 1,; Bohlke, Kari ScD 2; Baracos, Vickie E. PhD 3,; Smith, Thomas J. MD 4,; Loprinzi, Charles L. MD 5,; for the Cancer Cachexia Expert Panel; Bruera, Eduardo MD; Fabbro, Egidio del MD; Dixon, Suzanne MPH, MS, RD; Fallon, Marie MD; Herrstedt, Jorn MD, DMSci; Lau, Harold MD; Platek, Mary PhD, MS, RD; Rugo, Hope S. MD; Tan, Winston MD
doi : 10.1200/JCO.23.01280
Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer.
Springfeld, Christoph MD, PhD; Bu[Combining Diaeresis]chler, Markus W. MD, FACS (hon), FRCS (hon), FASA (hon); Neoptolemos, John P. MA, MB, BChir, MD, FRCS
doi : 10.1200/JCO.23.00779
Akathisia, an Easily Overlooked Side Effect.
Onishi, Hideki MD, PhD; Yoshioka, Akira MD, PhD; Sato, Izumi MPH, PhD; Uchida, Nozomu MD; Ishida, Mayumi CP, PhD
doi : 10.1200/JCO.23.00853
Erratum: Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
doi : 10.1200/JCO.23.01377
Erratum: Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
doi : 10.1200/JCO.23.01370
